CLINUVEL says it has met its recruitment target in its Phase 3 trial (CUV105) of SCENESSE (afamelanotide) in vitiligo, with more than 200 patients enrolled. …
CLINUVEL recruits 200 patients for Phase 3 vitiligo trial of SCENESSE
May 7, 2025 Australian Biotech
Latest Video
New Stories
-
Cartherics to present at the 2025 BIO International convention
May 28, 2025 - -
How can you not be sceptical about a rigged one-sided process?
May 27, 2025 - - Latest News -
Roche advances the development of innovative antibiotic
May 27, 2025 - - Latest News -
Australian-led ENZAMET prostate cancer trial to be presented at ASCO 2025
May 27, 2025 - - Latest News -
Leadership transition for medical affairs professional association
May 26, 2025 - - Latest News -
NSW Government to improve access to ADHD diagnosis and treatment
May 26, 2025 - - Latest News -
Immutep’s efti combination meets primary endpoint in Phase 2 soft tissue sarcoma
May 26, 2025 - - Australian Biotech